{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:23:16Z","timestamp":1761157396342,"version":"build-2065373602"},"reference-count":35,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Recently, it was demonstrated that copper complexes and 3,4-diaminopyridine can effectively reduce the activity of the botulinum neurotoxin light chain. The aim of the present study was to indicate that treatment with an antidote may have a major influence, not only on the extremely rare disease of botulism, but also on the much more frequently occurring side effects experienced during BoNT therapy. This was a retrospective chart review of patients who were regularly treated with BoNT for various indications. The percentage of patients with clinical signs of overdosing was determined. In patients with facial dystonia, double vision and ptosis occurred as side effects. In patients with cervical dystonia, neck weakness and dysphagia were observed as the most frequent side effects. In oromandibular and oropharyngeal dystonia, abnormal tongue movements and dysphagia occurred frequently. In writer\u2019s cramp and mild post-stroke hand spasticity, severe paresis of the injected and non-injected finger muscles was observed. Additionally, in the BoNT treatment of pain syndromes (such as tension headaches or migraines), neck weakness may occur. Across all indications for clinical BoNT applications, clinical signs of BoNT overdosing may occur in up to 5% of the BoNT-treated patients. Therefore, the development of an antidote for BoNT overdoses would be very much appreciated and would have a major influence on the management of BoNT therapy.<\/jats:p>","DOI":"10.3390\/medicina58070935","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T01:57:11Z","timestamp":1657850231000},"page":"935","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Necessity of a Locally Active Antidote in the Clinical Practice of Botulinum Neurotoxin Therapy: Short Communication"],"prefix":"10.3390","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1069-7684","authenticated-orcid":false,"given":"Harald","family":"Hefter","sequence":"first","affiliation":[{"name":"Department of Neurology, Medical Faculty, Heinrich Heine University of D\u00fcsseldorf, Moorenstrasse 5, D-40225 D\u00fcsseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3593-1852","authenticated-orcid":false,"given":"Sara","family":"Samadzadeh","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty, Heinrich Heine University of D\u00fcsseldorf, Moorenstrasse 5, D-40225 D\u00fcsseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/0014-4800(67)90007-X","article-title":"Experimental botulism in monkeys\u2014A clinical pathological study","volume":"6","author":"Herrero","year":"1967","journal-title":"Exp. Mol. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.285.8.1059","article-title":"Botulinum toxin as a biological weapon: Medical and public health management","volume":"285","author":"Arnon","year":"2001","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"802","DOI":"10.15585\/mmwr.mm6429a6","article-title":"Large Outbreak of Botulism Associated with a Church Potluck Meal\u2014Ohio, 2015","volume":"64","author":"McCarty","year":"2015","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jama.1997.03550050095041","article-title":"Botulism Surveillance and Emergency Response: A Public Health Strategy for a Global Challenge","volume":"278","author":"Shapiro","year":"1997","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/milmed\/148.12.901","article-title":"The covert use of chemical and biological warfare against United States Strategic Forces","volume":"148","author":"Hooper","year":"1983","journal-title":"Mil. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0161-6420(80)35127-0","article-title":"Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery","volume":"87","author":"Scott","year":"1980","journal-title":"Ophthalmology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000370245","article-title":"Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin","volume":"95","author":"Yiannakopoulou","year":"2015","journal-title":"Pharmacology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.toxicon.2015.06.019","article-title":"The thioredoxin reductase\u2014redox system cleaves the interchain disulphide bond of botulinum neurotoxins on the cytosolic surface of synaptic vesicles","volume":"107","author":"Pirazzini","year":"2015","journal-title":"Toxicon"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.febslet.2012.11.007","article-title":"The thioredoxin reductase-thioredoxin system is involved in the entry of tetanus and botulinum neurotoxins in the cytosol of nerve terminals","volume":"587","author":"Pirazzini","year":"2013","journal-title":"FEBS Lett."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"23784","DOI":"10.1016\/S0021-9258(20)80452-9","article-title":"Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E","volume":"268","author":"Schiavo","year":"1993","journal-title":"Biol. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"eabd7789","DOI":"10.1126\/scitranslmed.abd7789","article-title":"Neuronal delivery of antibodies has therapeutic effects in animal models of botulism","volume":"13","author":"McNutt","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2131\/jts.35.795","article-title":"Ouabain exacerbates botulinum neurotoxin-induced muscle paralysis via progression of muscle atrophy in mice","volume":"35","author":"Fujikawa","year":"2010","journal-title":"J. Toxicol. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lewis, G.E., and Wood, R.M. (1982). Effects of 3,4-Diaminopyridine in Cynomolgus Monkeys Poisoned with Type A Botulinum Toxin. Aminopyridines and Similarly Acting Drugs, Elsevier.","DOI":"10.1016\/B978-0-08-028000-4.50066-X"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0041-0101(94)00183-9","article-title":"Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparation","volume":"33","author":"Adler","year":"1995","journal-title":"Toxicon"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/0041-0101(96)83824-4","article-title":"Effects of 3,4-diaminopyridine on quantal acetylcholine release from neuromuscular junctions paralysed in vivo with botulinum type-F-toxin","volume":"34","author":"Molgo","year":"1996","journal-title":"Toxicon"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0041-0101(99)00231-7","article-title":"Antagonism of botulinum toxin A-mediated muscle paralysis by 3,4-diaminopyridine delivered via osmotic minipumps","volume":"38","author":"Adler","year":"2000","journal-title":"Toxicon"},{"key":"ref_17","unstructured":"Bradford, A.B., Machamer, J.B., Russo, T.M., and McNutt, P.M. (2022, May 23). 3,4-Diaminopyridine Reverses Paralysis in Botulinum Neurotoxin-intoxicated Diaphragms through Two Functionally Distinct Mechanisms. Available online: http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s10020-022-00487-4","article-title":"Antidotal treatment of botulism in rats by continuous infusion with 3,4-diaminopyridine","volume":"28","author":"Machamer","year":"2022","journal-title":"Mol. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/cc12880","article-title":"3,4-Diaminopyridine may improve neuromuscular block during botulism","volume":"17","author":"Friggeri","year":"2013","journal-title":"Crit. Care"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7264","DOI":"10.1021\/jacs.7b01084","article-title":"Metal Ions Effectively Ablate the Action of Botulinum Neurotoxin A","volume":"139","author":"Bremer","year":"2017","journal-title":"J. Am. Chem. Soc."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Hefter, H., and Samadzadeh, S. (2021). Effective Treatment of Neurological Symptoms with Normal Doses of Botulinum Neurotoxin in Wilson\u2019s Disease: Six Cases and Literature Review. Toxins, 13.","DOI":"10.3390\/toxins13040241"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fneur.2017.00035","article-title":"Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin","volume":"8","author":"Contarino","year":"2017","journal-title":"Front. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"636590","DOI":"10.3389\/fneur.2021.636590","article-title":"Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN\u00ae) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins","volume":"12","author":"Hefter","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"key":"ref_25","unstructured":"Royal College of Physicians BSoRM (2018). Spasticity in Adults: Management Using Botulinum Toxin, Royal College of Physicians. National Guidelines."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","article-title":"A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia","volume":"64","author":"Benecke","year":"2005","journal-title":"Neurology"},{"key":"ref_27","unstructured":"Innocenti, T. (2020). Adverse events associated with botulinum toxin A injection in the treatment of the upper and lower limbs muscles spasticity and dystonia: A systematic review with meta-analysis. Open Sci. Framew."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1468-1331.2009.02878.x","article-title":"Xeomin\u00ae in the treatment of cervical dystonia","volume":"16","author":"Benecke","year":"2009","journal-title":"Europ. J. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e001853","DOI":"10.1136\/bmjopen-2012-001853","article-title":"An open-label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin A (Dysport)","volume":"3","author":"Hefter","year":"2013","journal-title":"BMJ Open"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.parkreldis.2018.06.017","article-title":"Adverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo?","volume":"56","author":"Duarte","year":"2018","journal-title":"Park. Rel. Disord."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.toxicon.2017.09.006","article-title":"Design of modified botulinum neurotoxin A1 variants with a shorter persistence of paralysis and duration of action","volume":"139","author":"Scheps","year":"2017","journal-title":"Toxicon"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF03033930","article-title":"Clinical use of Non-A botulinum toxins: Botulinum toxin type C and botulinum toxin type F","volume":"9","author":"Eleopra","year":"2006","journal-title":"Neurotocicity Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1504\/TBJ.2010.039118","article-title":"Simultaneous or sequential administration of botulinum neurotoxin E does not reduce the paralysis caused by botulinum neurotoxin A in rat EDL muscle","volume":"1","author":"Adler","year":"2011","journal-title":"Botulinum. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1474-4422(14)70190-5","article-title":"Wilson\u2019s disease and other neurological copper disorders","volume":"14","author":"Bandmann","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.parkreldis.2018.01.007","article-title":"Long-term outcome of neurological Wilson\u00b4s disease","volume":"49","author":"Hefter","year":"2019","journal-title":"Park. Rel. Disord."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/7\/935\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:50:48Z","timestamp":1760140248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/7\/935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["medicina58070935"],"URL":"https:\/\/doi.org\/10.3390\/medicina58070935","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2022,7,14]]}}}